SK98798A3 - Combined pharmaceutical preparation containing lhrh-analogous substances and anti-estrogens for treating gynaecological disorders - Google Patents
Combined pharmaceutical preparation containing lhrh-analogous substances and anti-estrogens for treating gynaecological disorders Download PDFInfo
- Publication number
- SK98798A3 SK98798A3 SK987-98A SK98798A SK98798A3 SK 98798 A3 SK98798 A3 SK 98798A3 SK 98798 A SK98798 A SK 98798A SK 98798 A3 SK98798 A3 SK 98798A3
- Authority
- SK
- Slovakia
- Prior art keywords
- lhrh
- use according
- treatment
- analogue
- estrogens
- Prior art date
Links
- 229940046836 anti-estrogen Drugs 0.000 title claims abstract description 21
- 230000001833 anti-estrogenic effect Effects 0.000 title claims abstract description 21
- 239000000328 estrogen antagonist Substances 0.000 title claims abstract description 21
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 3
- 239000000126 substance Substances 0.000 title abstract 2
- 201000009273 Endometriosis Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000004458 Myoma Diseases 0.000 claims abstract description 9
- 230000001076 estrogenic effect Effects 0.000 claims abstract description 9
- 206010067572 Oestrogenic effect Diseases 0.000 claims abstract description 6
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 21
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 15
- 229960004622 raloxifene Drugs 0.000 claims description 14
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 13
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 13
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 13
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 7
- 108010083551 iturelix Proteins 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 6
- 108010000817 Leuprolide Proteins 0.000 claims description 5
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 5
- 229960004338 leuprorelin Drugs 0.000 claims description 5
- WDYSQADGBBEGRQ-APSDYLPASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2r,3r,4r,5r,6s) Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WDYSQADGBBEGRQ-APSDYLPASA-N 0.000 claims description 3
- 108010037003 Buserelin Proteins 0.000 claims description 3
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 3
- 108010069236 Goserelin Proteins 0.000 claims description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 3
- 229960002719 buserelin Drugs 0.000 claims description 3
- 108700008462 cetrorelix Proteins 0.000 claims description 3
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 3
- 229960003230 cetrorelix Drugs 0.000 claims description 3
- 229950004203 droloxifene Drugs 0.000 claims description 3
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 3
- 108010092834 ramorelix Proteins 0.000 claims description 3
- 229950000277 ramorelix Drugs 0.000 claims description 3
- 229940033942 zoladex Drugs 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 108010034529 leucyl-lysine Proteins 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 5
- 230000037182 bone density Effects 0.000 description 5
- 210000004696 endometrium Anatomy 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- -1 4-acetyl-aminophenyl Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000007106 menorrhagia Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19604231A DE19604231A1 (de) | 1996-01-29 | 1996-01-29 | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| PCT/EP1997/000395 WO1997027863A1 (de) | 1996-01-29 | 1997-01-29 | Pharmazeutisches kombinationspräparat aus lhrh-analoga und antiöstrogenen zur behandlung von gynäcologischen störungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK98798A3 true SK98798A3 (en) | 1999-03-12 |
Family
ID=7784640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK987-98A SK98798A3 (en) | 1996-01-29 | 1997-01-29 | Combined pharmaceutical preparation containing lhrh-analogous substances and anti-estrogens for treating gynaecological disorders |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7309691B2 (hu) |
| EP (1) | EP0877621A1 (hu) |
| JP (1) | JP2000505422A (hu) |
| KR (1) | KR19990082080A (hu) |
| CN (1) | CN1209750A (hu) |
| BG (1) | BG63248B1 (hu) |
| BR (1) | BR9707210A (hu) |
| CZ (1) | CZ239198A3 (hu) |
| DE (1) | DE19604231A1 (hu) |
| EA (1) | EA001178B1 (hu) |
| HU (1) | HUP9901288A3 (hu) |
| IL (1) | IL125557A0 (hu) |
| MX (1) | MX9806082A (hu) |
| NO (1) | NO983465L (hu) |
| PL (1) | PL328066A1 (hu) |
| SK (1) | SK98798A3 (hu) |
| TR (1) | TR199801452T2 (hu) |
| TW (1) | TW577735B (hu) |
| WO (1) | WO1997027863A1 (hu) |
| ZA (1) | ZA97741B (hu) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US6096764A (en) * | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
| DE69912422T2 (de) * | 1998-04-23 | 2004-08-19 | Zentaris Gmbh | Methode zur behandlung von fruchtbarkeitsstörungen |
| PT1229906E (pt) * | 1999-08-31 | 2008-01-18 | Bayer Schering Pharma Ag | Mesoprogestinas para o tratamento e prevenção de distúrbios ginecológicos hormonodependentes benignos |
| US8193252B1 (en) | 1999-08-31 | 2012-06-05 | Bayer Pharma AG | Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders |
| US7005418B1 (en) | 1999-09-23 | 2006-02-28 | Zentaris Gmbh | Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction |
| NZ534836A (en) * | 1999-09-23 | 2007-07-27 | Zentaris Gmbh | Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction |
| AU2001269439A1 (en) * | 2000-07-05 | 2002-01-14 | Takeda Chemical Industries Ltd. | Medicinal preparations for treating sex hormone-dependent diseases |
| DE10050831A1 (de) | 2000-10-05 | 2002-05-02 | Veyx Pharma Gmbh | Verfahren zum Zyklusstart bei weiblichen Zuchttieren |
| IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
| WO2002056903A2 (en) * | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| JP2003137814A (ja) * | 2001-08-10 | 2003-05-14 | Takeda Chem Ind Ltd | ＧｎＲＨアゴニストの併用剤 |
| US7705011B2 (en) | 2005-03-16 | 2010-04-27 | Masao Igarashi | Agent for treatment and prevention of endometriosos and uterine adenomyosis |
| EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| BR112012032189B1 (pt) * | 2010-06-16 | 2020-11-03 | Endorecherche, Inc | usos de um agonista ou antagonista de lhrh em associação com um modulador de receptor de estrogênio seletivo e com um precursor de esteróide sexual para a preparação de uma medicamento para o tratamento ou prevenção de doenças relacionadas com estrogênio e kits |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| US5457116A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods of inhibiting uterine fibrosis |
| US5451589A (en) * | 1993-12-21 | 1995-09-19 | Eli Lilly And Company | Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism |
| US5451590A (en) * | 1993-12-21 | 1995-09-19 | Eli Lilly & Co. | Methods of inhibiting sexual precocity |
| US5593987A (en) * | 1993-12-21 | 1997-01-14 | Eli Lilly And Company | Methods of inhibiting breast disorders |
| US6096764A (en) * | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
-
1996
- 1996-01-29 DE DE19604231A patent/DE19604231A1/de not_active Ceased
-
1997
- 1997-01-29 BR BR9707210A patent/BR9707210A/pt not_active IP Right Cessation
- 1997-01-29 IL IL12555797A patent/IL125557A0/xx unknown
- 1997-01-29 JP JP9527295A patent/JP2000505422A/ja not_active Ceased
- 1997-01-29 HU HU9901288A patent/HUP9901288A3/hu unknown
- 1997-01-29 PL PL97328066A patent/PL328066A1/xx unknown
- 1997-01-29 ZA ZA9700741A patent/ZA97741B/xx unknown
- 1997-01-29 CN CN97191940A patent/CN1209750A/zh active Pending
- 1997-01-29 SK SK987-98A patent/SK98798A3/sk unknown
- 1997-01-29 EA EA199800666A patent/EA001178B1/ru not_active IP Right Cessation
- 1997-01-29 KR KR1019980705802A patent/KR19990082080A/ko not_active Application Discontinuation
- 1997-01-29 US US09/117,357 patent/US7309691B2/en not_active Expired - Fee Related
- 1997-01-29 TR TR1998/01452T patent/TR199801452T2/xx unknown
- 1997-01-29 WO PCT/EP1997/000395 patent/WO1997027863A1/de not_active Application Discontinuation
- 1997-01-29 EP EP97902258A patent/EP0877621A1/de not_active Withdrawn
- 1997-01-29 CZ CZ982391A patent/CZ239198A3/cs unknown
- 1997-02-14 TW TW086101753A patent/TW577735B/zh active
-
1998
- 1998-07-28 NO NO983465A patent/NO983465L/no not_active Application Discontinuation
- 1998-07-29 BG BG102660A patent/BG63248B1/bg unknown
- 1998-07-29 MX MX9806082A patent/MX9806082A/es unknown
-
2001
- 2001-08-10 US US09/925,419 patent/US20020032156A1/en not_active Abandoned
-
2002
- 2002-07-31 US US10/207,907 patent/US20020198155A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1209750A (zh) | 1999-03-03 |
| ZA97741B (en) | 1997-07-30 |
| US20010041672A1 (en) | 2001-11-15 |
| TW577735B (en) | 2004-03-01 |
| BR9707210A (pt) | 1999-04-06 |
| US20020032156A1 (en) | 2002-03-14 |
| NO983465L (no) | 1998-09-18 |
| BG63248B1 (bg) | 2001-07-31 |
| IL125557A0 (en) | 1999-03-12 |
| PL328066A1 (en) | 1999-01-04 |
| NO983465D0 (no) | 1998-07-28 |
| TR199801452T2 (xx) | 1998-10-21 |
| EA199800666A1 (ru) | 1999-02-25 |
| BG102660A (en) | 1999-06-30 |
| JP2000505422A (ja) | 2000-05-09 |
| CZ239198A3 (cs) | 1998-11-11 |
| KR19990082080A (ko) | 1999-11-15 |
| WO1997027863A1 (de) | 1997-08-07 |
| US20020198155A1 (en) | 2002-12-26 |
| HUP9901288A2 (hu) | 1999-08-30 |
| EP0877621A1 (de) | 1998-11-18 |
| MX9806082A (es) | 1998-10-31 |
| EA001178B1 (ru) | 2000-10-30 |
| HUP9901288A3 (en) | 2000-03-28 |
| US7309691B2 (en) | 2007-12-18 |
| DE19604231A1 (de) | 1997-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2703243B2 (ja) | 避妊薬用としての性ステロイド放出と組合わされた黄体形成ホルモン放出ホルモン組成物の連続放出 | |
| RU2110274C1 (ru) | Способ лечения состояния, зависящего от эстрогенов яичников | |
| SK98798A3 (en) | Combined pharmaceutical preparation containing lhrh-analogous substances and anti-estrogens for treating gynaecological disorders | |
| US8236785B2 (en) | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method | |
| EP0994718B1 (en) | Gonadotropin releasing hormone antagonist | |
| Corbin et al. | Peptide Contraception: Antifertility Properties of LH‐RH Analogues | |
| JP2005501918A (ja) | 制御下の過排卵刺激におけるｈＣＧの使用 | |
| Wallach et al. | Clinical uses of luteinizing hormone-releasing hormone | |
| Herman et al. | Follicle cysts after menstrual versus midluteal administration of gonadotropin-releasing hormone analog in in vitro fertilization | |
| US7393834B2 (en) | LHRH-antagonists in the treatment of fertility disorders | |
| RU2181598C2 (ru) | Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения | |
| US5116818A (en) | Method and kit for contraception with GnRH-antagonist | |
| AU761274B2 (en) | Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders | |
| CA2244675A1 (en) | Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders | |
| Yenılmez et al. | The utilization areas of cabergoline in veterinary gynecology | |
| Neves-e-Castro et al. | Use of luteinizing hormone-releasing hormone analogs in non-neoplastic gynecologic conditions | |
| Forti | Clinicai applications of GnRH analogs | |
| CA2200541C (en) | Lhrh-antagonists in the treatment of fertility disorders | |
| EP0378533A1 (en) | METHOD AND KIT FOR CONTRACEPTION WITH GnRH-ANTAGONIST AND PROGESTIN | |
| Gordon et al. | GnRH Antagonists: Primate Models for Clinical Indications | |
| Helvacioglu | Gonadotropin Releasing Hormone Treatment | |
| WOMEN | MJK HARPER | |
| Schally et al. | STIMULATORY AND INHIBITORY ANALOGS OF LH-RH |